The nuclear receptor known as the androgen receptor (AR) is activated when either the androgenic hormones testosterone or dihydrotestosterone bind to it in the cytoplasm before moving into the nucleus. The receptor separates from supporting proteins after binding the hormone ligand, moves into the nucleus, dimerizes, and then activates transcription of androgen-responsive genes. The progesterone receptor is most similar to the androgen receptor, and progestins can block the androgen receptor when used in higher doses. The androgen receptor's primary role is that of a DNA-binding transcription factor that controls gene expression. The development and maintenance of the male sexual phenotype depend heavily on genes that are regulated by androgen. Complete androgen insensitivity (CAIS) is a condition that is also correlated with mutations in this gene.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V8411 | AC-262536 | 870888-46-3 | AC-262536 (AC262536) is anovel selective androgen receptor modulator (SARM) with beneficial anabolic effects. |
|
V10225 | ACP-105 | 899821-23-9 | ACP-105 (ACP105; ACP 105) is a novel, nonsteroidal and orally bioactive SARM (selective androgen receptor modulator) that has been investigated for the treatment of age-related cognitive decline. |
|
V1761 | Andarine (GTx-007) | 401900-40-1 | Andarine (formerly known as GTx-007;S-4;GTx007;S4) is an orally bioactive and selective non-steroidal androgen receptor (AR) agonist,specifically a selective androgen receptor modulator (SARM),that has potential usefulness in muscle wasting and osteoporosis. |
|
V1760 | Apalutamide (ARN-509) | 956104-40-8 | Apalutamide (formerly JNJ56021927;ARN509;JNJ-56021927;ARN-509; trade nameErleada), an approved anticancer drug,is a potent, selective and competitive, orally bioavailable AR/androgen receptor inhibitor with an IC50 of 16 nM in a cell-free assay. |
|
V1766 | AZD3514 | 1240299-33-5 | AZD3514 (AZD-3514;AZD 3514) is a novel, potent and orally bioavailableandrogen receptor downregulatorwith potential anticancer activity. |
|
V41443 | Bavdegalutamide (ARV-110) | 2222112-77-6 | Bavdegalutamide (ARV110; ARV-110) is an orally bioavailable PROTAC-based Androgen Receptor (AR) degrader with potentialanticancer activity. |
|
V1758 | Bicalutamide (Casodex; ICI-176334) | 90357-06-5 | Bicalutamide (formerly known as ICI-176334; CDX; trade names: Casodex in the USA and Cosudex in other countries), a marketed drug for treating PC (prostate cancer), is a potent, synthetic, nonsteroidalandrogen receptor (AR) antagonist with potential anticancer activity. |
|
V3472 | BMS-564929 | 627530-84-1 | BMS-564929 is anovel, highly potent, orally bioactive, nonsteroidal tissue selective androgen receptor (AR) modulator that binds to androgen receptor (AR) with aKiof 2.11±0.16 nM. |
|
V13466 | Clascoterone | 19608-29-8 | Clascoterone (cortexolone 17alpha-propionate; CB-03-01; Winlevi; Breezula) is a novel and potent androgen antagonist that has been approved in 2020 for topical use in the treatment of acne. |
|
V1768 | Cyproterone Acetate | 427-51-0 | Cyproterone acetate (Cyprone, Androcur, Cyprostat,Cyprohexal, Ciproterona, Cyproteron, Procur,Cyproteronum, Neoproxil, Siterone), an analog of17-hydroxyprogesterone, is an androgen receptor (AR) antagonist with potential antitumor activity. |
|
V32637 | D4-abiraterone | 154229-21-7 | D4-abiraterone is an active metabolite of abirateroneΔ4-Abiraterone (D4A) which is a CYP17A1 inhibitor and an androgen receptor antagonist (IC50 of 5.3 nM). |
|
V11512 | Danazol | 17230-88-5 | Danazol is a novel and potent analogue of the synthetic steroid ethisteroneacting as a testosterone gonadotropin inhibitor with weak androgenic effects. |
|
V1765 | Darolutamide (ODM-201;BAY-1841788) | 1297538-32-9 | Darolutamide (formerly known as BAY-1841788; ODM-201;BAY1841788;Nubeqa)is a novel and potentandrogen receptor (AR) antagonist with potential antitumor activity. |
|
V4725 | Dimethylcurcumin | 52328-98-0 | Dimethylcurcumin (formerly known as ASC-J9; GO-Y025) is anandrogen receptor(AR)degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion. |
|
V1757 | Enzalutamide (MDV3100) | 915087-33-1 | Enzalutamide (formerly MDV3100;MDV-3100; trade name: Xtandi) is an orally bioavailable, 2nd-generation and non-steroidal androgen-receptor (AR) antagonist with potential antineoplastic activity. |
|
V1762 | EPI-001 | 227947-06-0 | EPI-001 (EPI001; EPI 001) is a novel, potent small-molecule antagonist of AR-androgen receptor N-terminal domain (NTD) with potential antineoplastic activity. |
|
V1767 | Epiandrosterone | 481-29-8 | Epiandrosterone [also known as 3β-androsterone, Epi (17-ketosteroid epiandrosterone)]is a naturally occuring/endogenous steroid hormone with weak androgenic activity. |
|
V1764 | Flutamide (SCH 13521) | 13311-84-7 | Flutamide (also known as SCH13521; SCH-13521; trade names: Flucinom; Flugerel; Niftolid;Flutan;Oncosal etc. |
|
V3564 | GSK-2881078 | 1539314-06-1 | GSK 2881078 (GSK2881078) is a novel, potent and selective androgen receptor modulator (SARM) that can be potentially used for the treatment of cachexia. |
|
V3518 | KX-826 | 1272719-00-2 | This product is discontinued due to commercial reason. KX826( also known as Pyrilutamide ) is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of androgenetic alopecia (AGA) and acne vulgaris. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
